FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF V600E -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
Journal of Clinical Oncology · 01.09.2023 · 41 (25) · 4143-4153
DOI: 10.1200/jco.22.01420 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.09.2023. Verfasst von Sebastian Stintzing und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology, and Cancer Immunology (CCM), Charité-Universitaetsmedizin Berlin, Germany. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
PURPOSE BRAF V600E mutation is associated with a poor outcome in metastatic colorectal cancer (mCRC). This clinical trial investigated the efficacy of triplet chemotherapy (fluorouracil, folinic acid, oxaliplatin, and irinotecan) combined with either cetuximab or bevacizumab in patients with previously untreated BRAF V600E -mutant mCRC. PATIENTS AND METHODS In this controlled, randomized, open-label phase II trial, 109 patients were randomly assigned, 107 of whom were included into the full analysis set (FAS). Patients were randomly assigned in a 2:1 ratio to receive either FOLFOXIRI plus cetuximab in the experimental arm (n = 72) or FOLFOXIRI plus bevacizumab in the control arm (n = 35). The primary end point was objective response rate (ORR) according to RECIST 1.1., evaluated in patients treated according to protocol (ATP population). Progression-free survival (PFS), overall survival (OS), toxicity, and feasibility were analyzed as secondary end points. RESULTS Eighteen patients discontinued study treatment before the first tumor assessment, thus resulting in the ATP population of 89 patients. In these patients, ORR was 51% (30/59) in the cetuximab-based experimental arm and 67% (20/30) in the bevacizumab-based control arm (odds ratio, 1.93; 80% CI, 1.06 to 3.52; P = .92 [one-sided]). In the full analysis set, median PFS was significantly inferior in the experimental arm (6.7 months v 10.7 months; hazard ratio [HR], 1.89; P = .006). Median OS analyzed at an event rate of 64.5% showed a trend toward shorter survival in cetuximab-treated patients (12.9 months v 17.1 months; HR, 1.4; P = .20). CONCLUSION To our knowledge, FIRE-4.5 is the first prospective and randomized study investigating first-line treatment of BRAF V600E -mutant mCRC. FOLFOXIRI plus cetuximab does not induce a higher ORR when compared with FOLFOXIRI plus bevacizumab in first-line treatment of BRAF V600E -mutant mCRC. Bevacizumab-based chemotherapy remains the preferable first-line treatment of patients with BRAF V600E -mutant mCRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology, and Cancer Immunology (CCM), Charité-Universitaetsmedizin Berlin, Germany.
- German Cancer Consortium (DKTK), partner site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Oncology, LMU University Hospital, Munich, Germany.
- Department of Hepato-Gastroenterology, Poitiers University Hospital and University of Poitiers, Poitiers, France.
- Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany.
- Department of Hematology, Oncology, and Cancer Immunology (CBF), Charité-Universitaetsmedizin Berlin, Germany.
ORCID-Profile: Sebastian Stintzing, Kathrin Heinrich, David Tougeron, Dominik Paul Modest, Ingo Schwaner, Christoph Kahl, Anke Reinacher-Schick, Gerald Wolfgang Prager, Julien Taieb, Volker Heinemann
Zitieren
APA
Stintzing, S., Heinrich, K., Tougeron, D., Modest, D. P., Schwaner, I., Eucker, J., Pihusch, R., Stauch, M., Kaiser, F., Kahl, C., Karthaus, M., Müller, C., Burkart, C., Reinacher-Schick, A., Kasper-Virchow, S., Fischer von Weikersthal, L., Krammer-Steiner, B., Prager, G. W., Taieb, J., & Heinemann, V. (2023). FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF V600E -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. Journal of Clinical Oncology, 41(25), 4143-4153. https://doi.org/10.1200/jco.22.01420
Vancouver
Stintzing S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, et al. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF V600E -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. Journal of Clinical Oncology. 2023;41(25):4143-4153. doi:10.1200/jco.22.01420
BibTeX
@article{Stintzing2023,
author = {Stintzing, Sebastian and Heinrich, Kathrin and Tougeron, David and Modest, Dominik Paul and Schwaner, Ingo and Eucker, Jan and Pihusch, Rudolf and Stauch, Martina and Kaiser, Florian and Kahl, Christoph and Karthaus, Meinolf and Müller, Christian and Burkart, Christof and Reinacher-Schick, Anke and Kasper-Virchow, Stefan and Fischer von Weikersthal, Ludwig and Krammer-Steiner, Beate and Prager, Gerald Wolfgang and Taieb, Julien and Heinemann, Volker},
title = {FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF V600E -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {25},
pages = {4143--4153},
doi = {10.1200/jco.22.01420}
}
EUVIMED